Last reviewed · How we verify
NCT04143152
Pancreatic Cancer Biomarker Study
trial in Pancreatic Adenocarcinoma in 300 participants. Participants enrolled and being followed up; not accepting new ones.
31 August 2024
Quick facts
| Lead sponsor | Van Andel Research Institute |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 January 2021 |
| Primary completion | 31 August 2024 |
| Estimated completion | 31 October 2024 |
| Sites | 1 location across United States |
Conditions studied
- Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →
Sponsor
Van Andel Research Institute
Who can join
18 and older, any sex, with Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a non-treatment, blood collection study to evaluate biomarker panels for the diagnosis and prognosis of pancreatic cancer.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Diagnostic biomarkers for pancreatic cancer: An update.
Yang M, Zhang CY. · · 2021 · cited 14× · PMID 34963749 · DOI 10.3748/wjg.v27.i45.7862 -
BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients.
Park JH, Jo JH, Jang SI, Chung MJ, et al · · 2022 · cited 12× · PMID 35008403 · DOI 10.3390/cancers14010236 -
The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers.
Mottini C, Auciello FR, Manni I, Pilarsky C, et al · · 2024 · cited 6× · PMID 39020414 · DOI 10.1186/s13046-024-03117-5
Verify or expand the search:
- PubMed search for NCT04143152
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Adenocarcinoma
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07488676 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07493421 — To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating P · NA · recruiting
- NCT06896188 — 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLE · Phase 1 · recruiting
- NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
Other Van Andel Research Institute trials
Trials by the same sponsor.
- NCT04159207 — A Longitudinal Study of Inflammatory Pathways in Depression · completed
- NCT03526666 — Ascorbic Acid Levels in MDS, AML, and CMML Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04143152 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Van Andel Research Institute
- Last refreshed: 23 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04143152.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing